BIA calls on NICE to refresh evidence informing how rare disease medicines are evaluated and paid for
The UK BioIndustry Association (BIA) has today published research suggesting the UK’s medicines evaluation body is basing its methods and processes for evaluating medicines for rare diseases on outdated evidence.Rare insights: examining the social values of treating rare diseases , which has been supported by the BIA’s Rare Disease Industry Group (RDIG), presents the findings of primary research into public opinion on how treatments for rare diseases should be